Fortress Biotech, Inc. (NASDAQ: FBIO) Receives Average “Buy” Rating from Analysts


Shares of Fortress Biotech, Inc. (NASDAQ:FBIO – Get Rating) received a consensus “Buy” recommendation from the seven ratings companies that currently cover the company, Marketbeat Ratings reports. One investment analyst gave the stock a hold rating and five gave the company a buy rating. The 1-year average price target among analysts who have reported on the stock in the past year is $12.00.

Several stock analysts have recently weighed in on the stock. Roth Capital reiterated a “buy” rating on Fortress Biotech shares in a Tuesday, March 29 report. TheStreet downgraded shares of Fortress Biotech from a “c-” rating to a “d+” rating in a Monday, February 14 report. StockNews.com upgraded shares of Fortress Biotech from a “sell” rating to a “hold” rating in a Thursday, May 19 report. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $6.00 price target on Fortress Biotech shares in a Friday, May 13 report.

Several large investors have recently changed their positions in FBIO. Renaissance Technologies LLC increased its position in Fortress Biotech shares by 1,005.2% during the 1st quarter. Renaissance Technologies LLC now owns 1,101,300 shares of the biopharmaceutical company valued at $1,498,000 after purchasing an additional 1,001,653 shares last quarter. Acadian Asset Management LLC increased its stake in Fortress Biotech shares by 169.1% in Q1. Acadian Asset Management LLC now owns 424,693 shares of the biopharmaceutical company worth $575,000 after acquiring 266,853 additional shares in the last quarter. Morgan Stanley increased its stake in shares of Fortress Biotech by 768.2% in Q2. Morgan Stanley now owns 266,945 shares of the biopharmaceutical company worth $953,000 after acquiring 236,198 more shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Fortress Biotech in Q1 valued at $277,000. Finally, Wells Fargo & Company MN increased its stake in Fortress Biotech shares by 293.5% in the 4th quarter. Wells Fargo & Company MN now owns 227,638 shares of the biopharmaceutical company worth $569,000 after acquiring an additional 169,790 shares in the last quarter. Hedge funds and other institutional investors hold 30.92% of the company’s shares.

FBIO opened at $0.91 on Friday. Fortress Biotech has a 52 week low of $0.77 and a 52 week high of $4.49. The company has a quick ratio of 3.15, a current ratio of 3.31 and a leverage ratio of 0.46. The company has a market capitalization of $97.40 million, a P/E ratio of -1.05 and a beta of 2.29. The company’s 50-day moving average price is $1.01 and its 200-day moving average price is $1.69.

Fortress Biotech (NASDAQ:FBIO – Get Rating) last released its quarterly results on Thursday, May 12. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.10. Fortress Biotech had a negative net margin of 88.31% and a negative return on equity of 32.56%. The company posted revenue of $23.93 million for the quarter, versus a consensus estimate of $20.06 million. During the same quarter of the previous year, the company achieved EPS of ($0.11). On average, research analysts expect Fortress Biotech to post -0.77 EPS for the current fiscal year.

Fortress Biotech Company Profile (Get a rating)

Fortress Biotech, Inc., a biopharmaceutical company, develops and markets pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of moderate to severe non-nodular acne vulgaris; Targadox for severe acne; Exelderm cream for symptoms of ringworm and jock itch; Ceracade for dry skin; Luxamend for dressing and treating wounds; and Accutane capsules for severe recalcitrant nodular acne.

Recommended Stories

Analyst Recommendations for Fortress Biotech (NASDAQ: FBIO)



Get news and reviews for Fortress Biotech Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Fortress Biotech and related companies with MarketBeat.com’s free daily email newsletter.

About Sally Dominguez

Check Also

“My acne was so bad that I stopped having sex – but now I’ve found a natural cure”

Mandy Nazé, 29, says her face, forehead, chest, neck and back were badly affected and …